Challenge of prognostic uncertainty in the modern era of cancer therapeutics

Journal of Clinical Oncology

Volumn 34, Issue 30, 2016, Pages 3605-3608

  Temel, Jennifer S ^a   Shaw, Alice T ^a   Greer, Joseph A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CONFUSION (UNCERTAINTY); GENE MUTATION; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL INFORMATION; ONCOLOGIST; PRIORITY JOURNAL; TERMINAL CARE;

EID: 84992428504     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.8573     Document Type: Article

References (43)

1. Weeks JC, Cook EF, O'Day SJ, et al: Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 279:1709-1714, 1998
2. Weeks JC, Catalano PJ, Cronin A, et al: Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616-1625, 2012
3. Wright AA, Zhang B, Ray A, et al: Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300:1665-1673, 2008
4. Zhang B, Wright AA, Huskamp HA, et al: Health care costs in the last week of life: Associations with end-of-life conversations. Arch Intern Med 169:480-488, 2009
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
6. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
7. Shaw AT, Engelman JA: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370:2537-2539, 2014
8. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
9. Shaw AT, Gandhi L, Gadgeel S, et al: Alectinib in ALK-positive, crizotinibresistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 17:234-242, 2016
10. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
11. Jänne PA, Yang JC, Kim DW, et al: AZD9291 in EGFR inhibitor-resistant nonsmall-cell lung cancer. N Engl J Med 372:1689-1699, 2015
12. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334, 2013
13. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 372:2018-2028, 2015
14. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627-1639, 2015
15. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123-135, 2015
16. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330, 2015
17. Robert C, Karaszewska B, Schachter J, et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30-39, 2015
18. Long GV, Stroyakovskiy D, Gogas H, et al: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877-1888, 2014
19. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
20. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
21. Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-2017, 2015
22. Christakis NA, Lamont EB: Extent and determinants of error in doctors' prognoses in terminally ill patients: Prospective cohort study. BMJ 320:469-472, 2000
23. Gripp S, Moeller S, Bölke E, et al: Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 25:3313-3320, 2007
24. Maltoni M, Caraceni A, Brunelli C, et al: Prognostic factors in advanced cancer patients: Evidence-based clinical recommendations-A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240-6248, 2005
25. Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715-1724, 2012
26. Chochinov HM, Kristjanson LJ, Breitbart W, et al: Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: A randomised controlled trial. Lancet Oncol 12:753-762, 2011
27. Yun YH, Lee CG, Kim SY, et al: The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol 22:307-314, 2004
28. Mack JW, Weeks JC, Wright AA, et al: End-of-life discussions, goal attainment, and distress at the end of life: Predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol 28:1203-1208, 2010
29. El-Jawahri A, Traeger L, Park ER, et al: Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer. Cancer 120:278-285, 2014
30. Steinhauser KE, Christakis NA, Clipp EC, et al: Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 284:2476-2482, 2000
31. Hagerty RG, Butow PN, Ellis PA, et al: Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721-1730, 2004
32. Temel JS, Greer JA, Admane S, et al: Illness understanding in patients with advanced lung cancer. J Clin Oncol 27, 2009 (suppl; abstr 9515)
33. Temel JS, Greer JA, Admane S, et al: Code status documentation in the outpatient electronic medical records of patients with metastatic cancer. J Gen Intern Med 25:150-153, 2010
34. Mack JW, Cronin A, Taback N, et al: End-of-life care discussions among patients with advanced cancer: A cohort study. Ann Intern Med 156:204-210, 2012
35. Keating NL, Landrum MB, Rogers SO Jr, et al: Physician factors associated with discussions about end-of-life care. Cancer 116:998-1006, 2010
36. Moran T, Sequist LV: Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol 30:3330-3336, 2012
37. Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8:823-859, 2013
38. Jackson VA, Jacobsen J, Greer JA, et al: The cultivation of prognostic awareness through the provision of early palliative care in the ambulatory setting: A communication guide. J Palliat Med 16:894-900, 2013
39. Institute of Medicine: Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life. Washington, DC, The National Academies Press, 2015
40. Shaw AT, Friboulet L, Leshchiner I, et al: Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 374:54-61, 2016
41. Temel J, El Jawahri A, Greer J, et al: Randomized trial of early integrated palliative and oncology care. J Clin Oncol 34, 2016 (suppl; abstr 10003)
42. Temel JS, Greer JA, Muzikansky A, et al: Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733-742, 2010
43. Temel JS, Greer JA, Admane S, et al: Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: Results of a randomized study of early palliative care. J Clin Oncol 29:2319-2236, 2011